04/10/2021 – AB Science today announced that its clinical development program of masitinib in adult patients with mast cell activation syndrome (MCAS) has been approved by the U.S. Food and Drug Administration (FDA)

30/09/2021 – AB Science today reports its revenues for the first half of 2021 and provides an update on its activities

28/09/2021 – AB Science today announced that a new clinical trial with masitinib in patients with symptomatic mild and moderate COVID-19 has been approved by the Regulatory Authorities of Russia and South Africa

22/09/2021 – AB Science today announced that its clinical trial with AB8939 in adult patients with relapsed/refractory acute myeloid leukemia (AML) has been approved by Health Canada

20/09/2021 – AB Science announced that an abstract on the long-term survival of masitinib in ALS has been selected for a platform presentation at the Annual Meeting of the Spanish Society of Neurology

16/09/2021 – AB Science announced today that it has received authorization to resume patient enrollment in the phase 2 masitinib study of COVID-19 (AB20001)